Two cases of recurrent small-cell carcinoma of the uterine cervix treated with amrubicin as salvage chemotherapy

Small-cell carcinoma of the cervix (SCCC) is a rare and aggressive tumor; however, no definitive treatment guidelines for SCCC exist. A review of case series revealed that the most frequently used first-line chemotherapy regimen is combination etoposide and cis-platin, which is also used for small-cell lung cancer (SCLC). For recurrent SCLC, the utility of amrubicin (AMR) has recently been re-ported. However, optimal second-line chemotherapy for recurrent SCCC has remained unclear. Herein the authors report their experience using AMR as salvage chemotherapy for two patients with recurrent SCCC. AMR resulted in disease stabilization in both patients, with relatively long progression-free survival (PFS) of five and 14 months for platinum-refractory and -sensitive disease, respectively. No severe (grade >3) hematological or non-hematological toxicities were observed. In conclusion, AMR may be as effective and safe for recurrent SCCC as it is for recurrent SCLC. To further evaluate the efficacy and safety of AMR for recurrent SCCC, it is necessary to collect additional case studies or conduct a phase II trial.

Small cell carcinomas; Uterine cervix; Amrubicin; Recurrence.

[1] Abler V.A., Holm R., Nesland J.M., Kjørstad K.E.: “Small cell car-cinoma of the cervix: a clinicopathological study of 26 cases”. Can-cer, 1994, 73, 672.

[2] Kim Y.M., Jung M.H., Kim D.Y., Kim J.H., Kim Y.T., Nam J.H.: “Small cell carcinoma of the uterine cervix: clinicopathologic study of 20 cases in a single center”. Eur. J. Gynaecol. Oncol., 2009, 30, 539.

[3] Chen J., Macdonald O.K., Gaffney D.K.: “Incidence, mortality, and prognostic factors of small cell carcinoma of the cervix”. Obstet. Gy-necol., 2008, 111, 1394.

[4] McCusker M.E., Coté T.R., Clegg L.X., Tavassoli F.J.: “Endocrine tumors of the uterine cervix: incidence, demographics, and survival with comparison to squamous cell carcinoma”. Gynecol. Oncol., 2003, 88, 333.

[5] Satoh T., Takei Y., Treilleux I., Devouassoux-Shisheboran M., Led-ermann J., Viswanathan A.N., et al.: “Gynecologic Cancer Inter-Group (GCIG) consensus review for small cell carcinoma of the cervix”. Int. J. Gynecol. Cancer, 2014, 24, S102.

[6] Jotte R., Conkling P., Reynolds C., Galsky M.D., Klein L., Fitzgib-bons J.F., et al.: “Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy”. J. Clin. Oncol., 2011, 29, 287.

[7] Inoue A., Sugawara S., Yamazaki K., Maemondo M., Suzuki T., Gomi K., et al.: “Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung can-cer: North Japan Lung Cancer Study Group Trial 0402”. J. Clin. Oncol., 2008, 26, 5401.

[8] Murakami H., Yamamoto N., Shibata T., Takeda K., Ichinose Y., Ohe Y., et al.: “A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical On-cology Group Study (JCOG0901)”. Lung Cancer, 2014, 84, 67.

[9] von Pawel J., Jotte R., Spigel D.R., O’Brien M.E., Socinski

M. A., Mezger J., et al.: “Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer”. J. Clin. Oncol., 2014, 32, 4012.

[10] McCluggage W.G., Kennedy K., Busam K.J.: “An immunohisto-chemical study of cervical neuroendocrine carcinomas: Neoplasms that are commonly TTF1 positive and which may express CK20 and P63”. Am. J. Surg. Pathol., 2010, 34, 525.

[11] Ishida G.M., Kato N., Hayasaka T., Saito M., Kobayashi H., Katayama Y., et al.: “Small cell neuroendocrine carcinomas of the uterine cervix: a histological, immunohistochemical, and molec-ular genetic study”. Int. J. Gynecol. Pathol., 2004, 23, 366.

[12] Viswanathan A.N., Deavers M.T., Jhingran A., Ramirez P.T., Lev-enback C., Eifel P.J.: “Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence”. Gynecol. Oncol., 2004, 93, 27.

[13] Gardner G.J., Reidy-Lagunes D., Gehrig P.A.: “Neuroendocrine tu-mors of the gynecologic tract: A Society of Gynecologic Oncology (SGO) clinical document”. Gynecol. Oncol., 2011, 122, 190.

[14] Gadducci A., Carinelli S., Aletti G.: “Neuroendrocrine tumors of the uterine cervix: A therapeutic challenge for gynecologic oncologists”. Gynecol. Oncol., 2017, 144, 637.

[15] Wang K.L., Chang T.C., Jung S.M., Chen C.H., Cheng Y.M., Wu H. H., et al.: “Primary treatment and prognostic factors of small cell neuroendocrine carcinoma of the uterine cervix: a Tai-wanese Gynecologic Oncology Group study”. Eur. J. Cancer, 2012, 48, 1484.

[16] Lara P.N. Jr., Natale R., Crowley J., Lenz H.J., Redman M.W., Car-leton J.E., et al:. “Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124”. J. Clin. Oncol., 2009, 27, 2530.

[17] Roth B.J., Johnson D.H., Einhorn L.H., Schacter L.P., Cherng N. C., Cohen H.J., et al.: “Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Grou”. J. Clin. Oncol., 1992, 10, 282.

[18] Noda K., Nishiwaki Y., Kawahara M., Negoro S., Sugiura T., Yokoyama A., et al.: “Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer”. N. Engl. J. Med., 2002, 346, 85.

[19] Hanna N., Bunn P.A. Jr., Langer C., Einhorn L., Guthrie T. Jr., Beck T., et al.: “Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated exten-sive-stage disease small-cell lung cancer”. J. Clin. Oncol., 2006, 24, 2038.

[20] O’Brien M.E., Ciuleanu T.E., Tsekov H., Shparyk Y., Cuceviá B., Juhasz G., et al.: “Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer”. J. Clin. Oncol., 2006, 24, 5441.

[21] Frumovitz M., Munsell M.F., Burzawa J.K., Byers L.A., Rama-lingam P., Brown J., Coleman R.L.: “Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix”. Gynecol. Oncol., 2017, 144, 46.